^
Association details:
| Biomarker: | KRAS mutation + HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
Published date:
04/19/2022
Excerpt:
This study retrospectively evaluated patients with HER2-positive AGC who received first-line trastuzumab-containing chemotherapy...The KRAS MT group showed significantly worse response rates (16.7% vs. 66.2%, P = 0.016), progression-free survival [median, 4.8 vs. 11.6 months; hazard ratio (HR), 3.95; 95% CI, 1.60-9.76; P = 0.0029], and overall survival (11.5 vs. 23.6 months; HR, 3.80; 95% CI, 1.56-9.28; P = 0.033) compared to the KRAS wild-type group.
Secondary therapy:
Chemotherapy
DOI:
10.1007/s00432-022-03966-7
